Table 2.

Potential future antiplatelet agents in cardiovascular disease

Agent	Structure	Administration	Mechanism	Possible field of application
GLS‐409	Diadenosine tetraphosphate derivative	Intravenous	Synergistic inhibition of P2Y1 and P2Y12	ACS, PCI
PZ‐128	Cell‐penetrating lipopeptide	Intravenous	PAR‐1 inhibition	ACS, PCI
BMS‐986120	2‐methoxy‐6‐[6‐methoxy‐4‐[[5‐methyl‐2‐(4‐morpholinyl)‐4‐thiazolyl]methoxy]‐2‐benzofuranyl]‐imidazo[2,1‐b]‐1,3,4‐thiadiazole	Oral	PAR‐4 inhibition	CAD, PAD, CVD
Troα6, Troα10	Hexa‐ and deca‐peptides derived from the C‐terminal region of trowaglerix	Intravenous	Glycoprotein VI inhibition	ACS, PCI
BI1002494	(R)‐4‐{(R)‐1‐[7‐(3,4,5‐trimethoxy‐phenyl)‐[1,6]naphthyridin‐5‐yloxy]‐ethyl}pyrrolidin‐2‐one	Oral	Spleen tyrosine kinase inhibition	CAD, PAD, CVD
ML‐355	N‐(benzo[d]thiazol‐2‐yl)‐4‐((2‐hydroxy‐3‐methoxybenzyl)amino) benzenesulfonamide	Oral	12‐lipoxygenase inhibition	CAD, PAD, CVD

ACS, acute coronary syndrome; CAD, coronary artery disease; CVD, cerebrovascular disease; PAD, peripheral artery disease; PAR, protease‐activated receptor; PCI, percutaneous coronary intervention.